Log In
BCIQ
Print this Print this
 

Banzel, Inovelon, rufinamide (Banzel oral suspension) (E2080)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionTriazole derivative
Molecular Target Sodium channel
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationLennox-Gastaut syndrome
Indication DetailsAdjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 4 and up; Treat Lennox-Gastaut syndrome (LGS)
Regulatory Designation U.S. - Orphan Drug (Treat Lennox-Gastaut syndrome (LGS));
Switzerland - Orphan Drug (Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 4 and up)
PartnerEisai Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today